Merck Sharp + Dohme B.v.

Minoryx Therapeutics S.l.

Sander De Wilde

Wolter Ten Hoeve

Tjeerd Barf

Allard Kaptein

Arthur A Oubrie

Ana Maria García Collazo

Johannes Nicolaas Koek

Niels Hoogenboom

Eduard Willem Zwart

Johannes B M Rewinkel

Carsten Schultz-Fademrecht

Carsten Schultz-Fadermrecht

Ana Maria Garcia Collazo

Johannes BM Rewinkel

The disclosure provides a process of making the compound of Formula I, and pharmaceutically acceptable salts thereof; and the process of making the intermediate of Formula III; wherein PG is as defined as set forth in the specification.

Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]-methyl]-2,4-thiazolidinedione and salts thereof

The disclosure provides a process of making the compound of Formula I, and pharmaceutically acceptable salts thereof: and the process of making the intermediate of Formula III: wherein PG is as defined as set forth in the specification. 

Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

The present invention relates to compounds of general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used in the treatment of immune, autoimmune, inflammatory diseases, cardiovascular diseases, infectious diseases, bone resorption disorders, neurodegenerative diseases or proliferative diseases. 

MK2 inhibitors

Growing community of inventors

Oss, Netherlands

Sander De Wilde